80835-39-8

Upstream product

• 104-13-2 4-Butylaniline 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 89026-58-4 4-(4-Butyl-phenyl)-piperazine-1-carboxylic acid amide 
• 291510-82-2 1-[(2-Methoxyquinoxalin-3-yl)aminothiocarbonyl]-4-(4-but-ylphenyl) piperazine 
• 291510-52-6 1-[(2-Methoxyquinoxalin-3-yl)aminocarbonyl]-4-(4-butylph-enyl)-piperazine 
• 291510-15-1 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(4-butylphenyl)piperazine 
• 89026-63-1 4-(4-Butyl-phenyl)-piperazine-1-carbonitrile 

Relevant academic research and scientific papers

New pyrimido[5,4-b]indoles as ligands for α1-adrenoceptor subtypes

A new series of compounds were designed as structural analogues of the α1-AR ligand RN5 (4), characterized by a tricyclic 5H-pyrimido[5,4-b]indole-(1H,3H)2,4-dione system connected through an alkyl chain to a phenylpiperazine (PP) moiety. These compounds were synthesized and tested in binding assays on human α1A-AR, α1B-AR, and α1D-AR subtypes expressed in HEK293 cells. Several structural modifications were performed on the PP moiety, the tricyclic system, and the connecting alkyl chain. Many of the new molecules showed a preferential affinity for the α1D-AR subtype. Some compounds, including 39 and 40, displayed substantial α1D-AR selectivity with respect to α1A-AR, α1B-AR, serotonergic 5-HT1A, 5-HT1B, 5-HT2A, and dopaminergic D1 and D2 receptors. Two conformationally rigid analogues of 4, useful for studying the architecture of the receptor/ligand complex, were also prepared and tested. A subset of the new compounds was then used to evolve a preliminary pharmacophore model for α1D-AR antagonists, based on a more generalized model we had developed for α1-AR antagonists. This new model rationalized the relationships between structural properties and biological data of the pyrimido[5,4-b]indole compounds, as well as other compounds.

Practical method for parallel synthesis of diversely substituted 1-phenylpiperazines

A simple and practical method to prepare 'libraries' of substituted 1-phenylpiperazine building blocks in parallel format has been developed.

PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION

The invention relates to new piperazine-pieridine compounds having anti-viral activity and particularly anti-HCV activity. The invention further relates to pharmaceutical compositions comprising compounds according to the invention.